The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma

Antonio Russo, Daniela Petriella, Ettore Fistola, Antonio Russo, Gianmauro Numico, Evaristo Maiello, Stefania Tommasi, Nicola Silvestris, Giuseppe Colucci, Giuseppe Tonini, Daniele Santini, Daniele Santini

Risultato della ricerca: Articlepeer review

16 Citazioni (Scopus)


Wild-type KRAS status is required but not sufficient to confer sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer patients. As a consequence, one of the major challenges is to identify, in non-mutant KRAS patients, other markers that can predict lack of response to this therapy. Small series have investigated the clinical effect of PIK3CA mutations on resistance to anti-EGFR mAbs and discrepant results have been observed. Furthermore, PTEN loss in metastases may be predictive of resistance to anti-EGFR mAbs, even if PTEN determination is far from an immediate clinical application. The introduction of modulators of the PI3K/AKT/mTOR pathway as potential targeted anticancer drugs is encouraging, but this attractive therapy option is still at an early stage of development. Copyright © 2010 S. Karger AG.
Lingua originaleEnglish
pagine (da-a)69-74
Numero di pagine6
Stato di pubblicazionePublished - 2010

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2730???
  • ???subjectarea.asjc.1300.1306???


Entra nei temi di ricerca di 'The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma'. Insieme formano una fingerprint unica.

Cita questo